Clinical Trial · NCT02241668

Fluoro-L-Thymidine Positron Emission Tomography (FLT PET) vs. Adv. Magnetic Resonance (MR) Techniques in Recurrent Glioma

Overview

The goal of this clinical research study is to learn if using a new imaging solution, 3'-Deoxy-3'-18f-Fluorothymidine, in a positron emission tomography (PET) scan can help doctors determine if your brain lesion is from the tumor returning or the effects of previous treatments. The results of this imaging scan (called an FLT PET scan) will be compared to the results of a Magnetic Resonance Imaging scan, which you have already had or are scheduled to have outside of this study.

Sponsor

MD Anderson Cancer Center

Phase

N/A

Contacts

Eric Rohren, MD, PHD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT02241668

Drug / Compound

Fluorothymidine

Isotope(s):

Target(s):

cytosolic thymidine kinase 1

Ligand Class: Small Molecules

Eligibility

Inclusion

Patient agrees to undergo, prior to the procedure, FLT PET at CABI
Patient has received as part of their care the Brain Tumor Imaging protocol.
Patient's clinician based on the clinical and MR information wants to proceed with biopsy or surgical resection within 30 days from when the brain tumor MR protocol was performed. The patient meets with the neurosurgeon and agrees to surgical biopsy or resection.
Patient had diffuse glioma (WHO grade 2 - 4) and as part of their treatment received radiation therapy and Temozolomide (a first-line chemotherapeutic agent).
Patient will have subsequently developed an enhancing brain mass greater than 1cm in diameter, at least 6 months after finishing radiation therapy (to differentiate from the more acute treatment related effect of "pseudo-progression").
Patient is a candidate for cerebral tumor resection due to an enhancing brain lesion, with history of previous pathologically proven primary brain tumor (WHO grade II-IV diffuse glioma)
As the predominate means of determining TRN versus recurrent glial tumor at MD Anderson, a brain tumor/ necrosis protocol is ordered as clinically indicated.
Patient is able to understand and give consent to participation in the study

Exclusion

Pregnant or lactating (Based on self-reported and clinical care testing with physicians before study participation)
The patient is found to have unfavorable anatomy to indicate that stereotactic biopsy/ resection could not be safely performed
Allergy to Fluoro-L-Thymidine
Claustrophobia that does not readily respond to oral medication